All views/posts are my own; vaccines for life; proteins are beautiful; vaccine design; viral immunity; host-vaccine interface; vaccine immunologist; cat dad ORCiD: 0000-0001-5767-1532
Just out📢 Our new paper published in @natmicrobiol.nature.com describes highly potent cross-neutralizing human monoclonal antibodies against H5Nx influenza viruses. Close collaboration with Sara Andrews lab and Tongqing Zhou lab at the VRC. Link to the article: rdcu.be/eKV9T 1/2
📢Hot off the press! Our latest work studying #influenza broadly neutralizing antibody development in humanized mice. Huge thanks to everyone involved in the study🙏 #NIAID #VRC #Ragon #Scripps www.cell.com/cell-reports...
Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stemAtaca et al. describe a pathway to generate cross-reactive B cells against influenza
hemagglutinin by engaging a subdominant immunoglobulin germline-encoded motif through
prime-boost vaccination in IG...www.cell.comHot off the press! Our latest paper on #influenza neuraminidase (NA) antibodies has just been published in Immunity. Lederhofer et al. Isolated and characterized human antibodies to the NA ‘dark side’ that are broadly cross-reactive and protective. www.cell.com/immunity/ful...
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidaseInfluenza neuraminidase (NA) is underappreciated as a vaccine target owing to its incomplete epitope landscape. Lederhofer et al. isolated human monoclonal antibodies to NA underside (i.e., dark side)...www.cell.com